Stockscreener 앱 받기
16.00
8.18%
1.21
전일 마감가:
$14.79
열려 있는:
$14.84
하루 거래량:
184.22K
Relative Volume:
0.43
시가총액:
$1.06B
수익:
순이익/손실:
주가수익비율:
-
EPS:
-
순현금흐름:
1주 성능:
-3.79%
1개월 성능:
-27.77%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$0.00
$0.00
1주일 범위
$14.60
$16.89
52주 변동 폭
$14.60
$25.93
Latigo Biotherapeutics, Inc. Common Stock Stock (LTGO) Company Profile
Compare LTGO vs VRTX, MRNA, REGN, ARGX, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LTGO
Latigo Biotherapeutics, Inc. Common Stock
|
16.00 | 1.06B | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
508.89 | 128.98B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
212.54 | 84.85B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
765.84 | 78.85B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
818.91 | 51.50B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
192.94 | 41.36B | 742.00K | -1.37B | -1.07B | -7.0731 |
Latigo Biotherapeutics, Inc. Common Stock Stock (LTGO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-09-01 | 개시 | Goldman | Buy |
| 2026-09-01 | 개시 | Guggenheim | Buy |
| 2026-09-01 | 개시 | Jefferies | Buy |
| 2026-09-01 | 개시 | Leerink Partners | Outperform |
Latigo Biotherapeutics, Inc. Common Stock 주식(LTGO)의 최신 뉴스
Latigo Biotherapeutics, Inc. Common Stock (NASDAQ: LTGO) Stock Price, News & Analysis - kalkine.ca
Latigo Biotherapeutics, Inc. Common Stock (LTGO) Earnings Reports & Dates - FXEmpire
Latigo Biotherapeutics Q2 Results: EPS loss narrows 24% YoY - scanx.trade
Latigo Biotherapeutics (LTGO) draws 4.45M-share stake from Deep Track - Stock Titan
Sanofi Converts Series B Preferred Stock and Convertible Note into Latigo Biotherapeutics Common Shares Following IPO - Kalkine Media
Latigo Biotherapeutics Completes IPO and Updates Governance - TipRanks
Latigo Biotherapeutics (LTGO) On IPO And Trial Data Looks About Right Valued - Yahoo Finance
Latigo Biotherapeutics (Nasdaq:LTGO)Stock Analysis - Simply Wall Street
Latigo Biotherapeutics Prices Upsized $345.6 Million Initial Public Offering - quiverquant.com
Latham & Watkins Advises on Latigo Biotherapeutics’ Upsized US$345.6 Million Initial Public Offering - Latham & Watkins LLP
Latigo Biotherapeutics Announces Pricing of Upsized $345.6 Million Initial Public Offering - GlobeNewswire
Latigo Biotherapeutics prices $345.6M IPO at $18 per share - Investing.com
Latigo Biotherapeutics files for Nasdaq IPO at up to $18 per share - Investing.com
Latigo Biotherapeutics files for $256M-$288M Nasdaq IPO - scanx.trade
Latigo Biotherapeutics Commences IPO Process For Pain Treatment Pipeline (Pending:LTGO) - Seeking Alpha
Latigo Biotherapeutics, Inc. Common Stock (LTGO) 재무 분석
Latigo Biotherapeutics, Inc. Common Stock (LTGO)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
Latigo Biotherapeutics, Inc. Common Stock 주식 (LTGO) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Tananbaum James B. | Director |
Aug 10 '26 |
Buy |
18.00 |
140,000 |
2,520,000 |
2,008,024 |
5.04%
자본화:
|
볼륨(24시간):